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Abstract
Background—Emerging evidence suggests that CNS injury and neurocognitive impairment
persist in the setting of chronic HIV infection and combination antiretroviral therapy (CART). Yet
whether neurological injury can progress in this setting remains uncertain.
Methods—Magnetic resonance spectroscopy, neurocognitive and clinical assessments were
performed over two years in 226 HIV-infected individuals on stable CART, including 138
individuals who were neurocognitively asymptomatic (NA). Concentrations of N-acetylaspartate
(NAA), creatine (Cr), choline (Cho), myoinositol (MI), and glutamate/glutamine (Glx) were
measured in the midfrontal cortex (MFC), frontal white matter (FWM) and basal ganglia (BG).
Longitudinal changes in metabolite levels were determined using linear mixed effect models, as
were metabolite changes in relation to global neurocognitive function.
Results—HIV-infected subjects showed significant annual decreases in brain metabolite levels
in all regions examined, including NAA (2.95%), Cho (2.61%) in the FWM; NAA (1.89%), Cr
(1.84%), Cho (2.19%) and Glx (6.05%) in the MFC; and Glx (2.80%) in the BG. Similar
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metabolite decreases were observed in the NA and subclinically impaired subgroups, including
subjects with virologic suppression in plasma and CSF. Neurocognitive decline was associated
with longitudinal decreases in Glx in the FWM and the BG, and in NAA in the BG.
Conclusions—Widespread progressive changes in the brain, including neuronal injury, occur in
chronically HIV-infected persons despite stable antiretroviral treatment and virologic suppression
and can lead to neurocognitive declines. The basis for these findings is poorly understood and
warrants further study.
BACKGROUND
The successful suppression of HIV infection afforded by combination antiretroviral therapy
(CART) has led to a significant decrease in systemic as well as brain complications,
including neurocognitive and functional impairment, commonly referred to as AIDS
dementia complex (ADC) or HIV-associated neurocognitive disorder (HAND) (Antinori et
al, 2007; Hammer et al, 2006; Navia et al, 1986a; Navia et al, 1986b; Palella et al, 1998;
Robertson et al, 2007; Sacktor et al, 2002). Although dementia has become relatively rare in
settings with ready access to CART, milder forms of HAND remain common, with nearly
50% of chronically treated people showing neurocognitive impairment, comparable to rates
reported pre-CART (Heaton et al, 2010; Heaton et al, 2011; Tozzi et al, 2007). Furthermore,
increasing evidence largely drawn from neuroimaging studies suggest that brain pathology
persists in CART-treated individuals (Cardenas et al, 2009; Cohen et al, 2010a; Cohen et al,
2010b; Harezlak et al, 2011; Thompson et al, 2005). Nonetheless, it remains unclear whether
brain injury can further progress in the setting of stable disease and treatment, particularly
among neurocognitively asymptomatic individuals.
Proton magnetic resonance spectroscopy (MRS) provides a sensitive non-invasive method to
measure specific cerebral metabolites that reflect neuronal and glial dysfunction and
neuroinflammation. Numerous cross-sectional studies in HIV-infected persons and in SIV
macaque model have described a consistent pattern of metabolite abnormalities in both grey
and white matter brain regions, particularly in the frontal white matter and basal ganglia,
comprising of alterations in N-acetylaspartate (NAA), a marker of neuronal metabolism, and
choline-containing compounds (Cho) and myoinositol (MI), markers of cell membrane
damage and glial cell activity (Chang et al, 2004; Harezlak et al, 2011; Lentz et al, 2009;
Lopez-Villegas et al, 1997; Meyerhoff et al, 1999; Mohamed et al, 2010; Paul et al, 2007;
Tracey et al, 1996; Tracey et al, 1997; Urenjak et al, 1993; Yiannoutsos et al, 2004).
Metabolite abnormalities have also been associated with disease history, neurocognitive
function, and volumetric brain abnormalities (Chang et al, 2004; Cohen et al, 2010a;
Harezlak et al, 2011; Mohamed et al, 2010; Paul et al, 2007; Yiannoutsos et al, 2004).
Despite considerable evidence of HIV-associated brain disease, there have been no
published longitudinal studies to date of metabolite abnormalities in the setting of chronic
infection and treatment. The HIV Neuroimaging Consortium (HIVNC) was formed to
examine such changes in a prospective multicenter cohort of chronically HIV-infected
individuals with history of advanced disease (nadir CD4 < 200 cells/mL) on stable CART.
In a recent cross-sectional MRS study of 240 HIV- infected individuals, we reported
significant elevations in Cho and MI in all groups, while decreased NAA levels were
observed only among those with neurocognitive impairment (Harezlak et al, 2011). The
current prospective MRS and neurocognitive study was performed in 226 of these
individuals, including 138 neurocognitively asymptomatic individuals, over two years. We
hypothesized that, despite stable antiretroviral treatment, such individuals will show
progressive changes in cerebral metabolite levels, even in the setting of virologic
suppression. In addition, we hypothesized that such changes will be associated with
neurocognitive decline.
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Participants included 226 HIV-infected individuals who were enrolled in a longitudinal
study of HIV-associated brain injury at the following sites: University of California San
Diego, University of California Los Angeles (UCLA), Harbor-UCLA Medical Center,
Stanford University, University of Colorado, University of Pittsburgh, and Rochester
University. Demographic and clinical characteristics are shown in Table 1. All participants
gave written informed consent, and institutional review boards at each site approved the
protocol. Inclusion criteria included: nadir CD4 level < 200 cells/ml, stable FDA-approved
antiretroviral regimen ≥ 12 consecutive weeks; hemoglobin > 9.0 gm/dl; serum creatinine ≤
3x upper limit of normal (ULN); AST (SGOT), ALT (SGPT), and alkaline phosphatase ≤
3xULN. Exclusion criteria included: neurologic conditions including seizure disorder,
stroke, head trauma with loss of consciousness > 30 minutes, multiple sclerosis, brain
infection apart from HIV, and brain neoplasms; history of severe psychiatric disorders;
active alcohol and substance abuse within 6 months of study; diabetes mellitus with a fasting
glucose > 140 mg/dl.
Clinical Assessments
Participants underwent repeated neuroimaging, neurological, and neuropsychological
assessments as previously described (Harezlak et al, 2011). Neuropsychological evaluation
was performed in cognitive domains most implicated in HIV infection, including processing
speed, verbal fluency, executive functioning, working memory, learning and memory, and
psychomotor function (Heaton et al, 1995). Individual tests in each cognitive domain are
listed in Table 2. The most updated demographically corrected norms for each test were
used to convert individual test scores into standard scores (T scores, mean = 50, SD = 10). A
previously validated algorithm was used to derive a Global Deficit Score (GDS) for each
participant reflecting the overall degree of cognitive impairment. Specifically, the
demographically corrected T scores on individual neuropsychological measures were
converted to deficit scores ranging from 0 (no impairment) to 5 (severe impairment). The
GDS was then derived by averaging the deficit scores for all measures. Previous studies
have demonstrated the utility of the GDS in detecting cognitive impairment in HIV-infected
individuals (Carey et al, 2004; Heaton et al, 1995).
AIDS dementia complex (ADC) staging was performed by a trained clinician at each site
and was based on the neurological examination, assessment of functional impairment, and
neuropsychological performance as previously described (Harezlak et al, 2011). Subsequent
to the inception of this study, a new nosologic classification for HAND was proposed, with
ADC stage 0 (asymptomatic) corresponding to neurocognitively normal, stage 0.5
(subclinical) to asymptomatic neurocognitive impairment (ANI), stage 1 (symptomatic)
corresponding to mild neurocognitive disorder (MND), stage 2 or greater to HIV-associated
dementia (HAD) (Antinori et al, 2007).
MRS Acquisition and Processing
1H MRS spectra were acquired with 1.5-tesla General Electric magnetic resonance systems
(GE Healthcare, Waukesha, WI) at 7 participating sites using the GE quadrature head coil
and the manufacturer’s PRESS sequence. Field homogeneity and water suppression were
adjusted using automated algorithms from GE. Water suppressed spectra were collected
with TE/TR = 35/3000ms, bandwidth = 2500 Hz, 128 averages. In addition, a customized
pulse program was run to automatically collect single-scan, fully relaxed water FIDs from
each voxel at 7 different echo times. (TE = 35, 45, 65,100, 200, 500 and 1500 ms; TR = 15
s). From this, voxel partial volumes were determined to correct absolute metabolite
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concentrations (Ernst et al, 1993; Kreis et al, 1993). Regions of interest (ROI) 6 cc in
volume were prescribed in the midfrontal cortical gray matter located in the anterior
cingulate (MFC), frontal white matter located in the centrum semiovale (FWM), and basal
ganglia (BG). Laterality of the FWM and BG ROIs were alternated between participants but
maintained for repeat studies for each participant.
For quality control, sites were required to acquire a phantom spectrum within 24 hours of
each in vivo scan, using the identical MRS protocol as described above. The quality of the
MR spectra and voxel locations were monitored continuously University of Hawaii, based
on visual inspection and outputs from the LC Model spectral analysis software (Provencher,
2001), with unsuppressed water FID at TE = 35ms used for eddy-current correction. The
%SD (estimated standard deviations as percent of the estimated concentrations) and FWHM
(full width at half maximum, an estimate of peak width) were used to determine spectrum
quality. %SD of less than 20 and FWHM of less than 0.1 ppm constitute a reliable estimate
for a particular metabolite. Both absolute concentration and metabolite/Cr ratio were
computed for N-acetylaspartate (NAA), myoinositol (MI), choline-containing compounds
(Cho), glutamate+glutamine (Glx), and creatine (Cr). The coefficient of variation of the
metabolite estimates were <15%. Analysis of the phantom data from the current study
showed that the variability in measurements of metabolite ratios was smaller than the
variability in the study population, consistent with our reported findings in an independent
cohort (Lee et al, 2003). The variability in the phantom metabolite ratio between the seven
sites did not exceed 7% from the overall mean with most of the variations falling within
2-3%. Longitudinal analysis of phantom measurements taken at all sites also showed limited
variability in metabolite concentrations over time.
Statistical Analysis
Longitudinal analyses were performed using linear mixed effect models with length of time
since enrollment as an independent covariate and participant-specific random intercepts and
slopes (Laird and Ware, 1982). The annual rates of change and their associated standard
errors were estimated based on the regression coefficients corresponding to the mean
metabolite levels at baseline and the change in their concentrations over the 2-year time
period. Additional longitudinal analyses were done for participants with undetectable plasma
HIV RNA (N = 184) as well as undetectable CSF HIV RNA at baseline (N = 51). In
addition, we determined the rates of change for each clinical group defined by baseline ADC
stages 0, 0.5, and 1+ (see Clinical Assessments section above). To determine disease
stability, the longitudinal change in CD4 count and the proportion of subjects with
detectable plasma HIV RNA levels were assessed by linear and generalized linear mixed
models, respectively. Linear mixed methods analyses were also used to determine the
relationships between the rates of changes in metabolite levels and changes in global
neurocognitive function. First, we predicted the participant-specific rates of both metabolite
change and neurocognitive change using individual random intercepts and slopes. Then the
Pearson’s product moment correlations were estimated between the individual predicted
metabolite rates and neurocognitive score rates, and tested for the difference of these
correlations from zero using Fisher’s Z transform.
RESULTS
Cohort
Median age of participants was 47 years, while median duration of HIV infection was 11
years at baseline. All participants had history of advanced immunosuppression (median
nadir CD4 = 37 cells/ml), but a median current CD4 level of 326, consistent with successful
immunological restoration in response to antiretroviral therapies. The majority of
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participants were maintained on the same CART regimen for at least 1.5 years, with 81%
showing undetectable plasma HIV RNA levels. CSF HIV RNA levels were available for 82
participants, of which 60 (73%) were undetectable; while both plasma and CSF HIV RNA
were undetectable in 51 participants (62%). Longitudinal analyses examining HIV disease
stability during the study showed that mean CD4 levels increased by 6.9% over two years,
while the percentage of patients with undetectable plasma RNA remained stable at around
80%.
Longitudinal Metabolite Changes in the Whole Cohort
Significant decreases in absolute concentrations were observed in all brain regions
examined. The FWM showed significant annual decreases in NAA (2.95%, p < .0001) and
Cho (2.61%, p = .0001). The MFC also showed significant decreases in NAA (1.89%, p = .
0007), Cr (1.84%, p = .0059), Cho (2.19%, p = .0123, and Glx (6.05%, p < .0001). A
marginal decrease in MI was found in the MFC (1.81%, p = .0578). The BG showed a
significant decrease in only Glx ≥ (2.80%, p = .0043). Analyses of metabolite/Cr ratios
showed similar patterns of change in fewer brain regions. Significant decreases in NAA/Cr
(2.51%, p < .0001) and Cho/Cr (1.74%, p = .0123) were observed in the FWM, while the
MFC showed decreases in Glx/Cr (3.84%, p < .0001). No significant changes in metabolite/
Cr ratios in the BG were found. Table 4 shows estimated annual changes in all measured
absolute metabolite concentrations and metabolite/Cr ratios in the three brain regions.
The estimated rates of change in the phantom metabolite levels were much smaller than
those found in the study cohort. Specifically, the rates of change in absolute concentrations
were -1.10% for NAA, -0.93% for Cr, and -1.18% for Cho, while rates of change observed
in the study cohort were between 1.7 and 2.7 times larger in magnitude for metabolites
showing significant changes. Similarly, the rates of change in the relative concentrations
were -0.37% for NAA/Cr and -0.63% for Cho/Cr ratio. Again, the significant changes in the
metabolite ratios were between 2.8 and 6.8 times larger in magnitude in the cohort.
Longitudinal Changes by Neurocognitive Status
To examine whether metabolite changes differed with neurocognitive status, longitudinal
analyses of metabolite levels were performed in subgroups stratified according to ADC
stage (Table 4). Overall, NA (ADC 0) and subclinically impaired (ADC 0.5) subjects
showed similar patterns of metabolite changes, including significant decreases in NAA and
Cho in the FWM, and decrease in Glx in the MFC. In addition, NA subjects showed
significant decreases in NAA and Cr in the MFC, while participants in the subclinical group
showed significant decreases in Cho in the MFC and Glx in the BG. Symptomatic subjects
(ADC stage ≥1 showed relatively fewer metabolite changes, including significant decreases
in Glx in the MFC, in addition to decreases in Cr and Cho in the BG.
Longitudinal Changes in Participants with Undetectable HIV RNA
To further examine whether significant metabolite changes occurred even in virologically
suppressed individuals, we examined longitudinal metabolite changes in a subgroup of
subjects with undetectable plasma HIV RNA at baseline (N=184) and another subgroup with
undetectable HIV RNA in both plasma and CSF (N=51) (Table 4). Participants with plasma
virologic suppression showed similar patterns of metabolite changes as in the whole cohort.
In participants with virologic suppression in both plasma and CSF (N = 51), significant
decreases were found in NAA in the FWM, Glx and MI in the MFC, and NAA in the BG.
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Changes in Metabolite Levels Relative to Cognitive Decline
We assessed whether changes in metabolite levels were associated with changes in global
cognitive function. Increase in the GDS score (reflecting cognitive decline) was significantly
associated with decreases in Glx/Cr in the FWM (p = .0319) and Glx/Cr in the BG (p = .
0468). A marginal relationship was found between increased GDS and decreased absolute
NAA level in the BG (p = .0568).
DISCUSSION
Whether chronically HIV-infected individuals can develop progressive brain abnormalities
despite successful viral suppression and immunological restoration in response to
antiretroviral treatment has remained an important yet unresolved question. In this
prospective study, we found significant annual decreases ranging from 2% to 6% in the
levels of several metabolites, notably NAA and Glx, markers of neuronal and glial cell
function, in both cortical and subcortical brain regions. The current results are remarkable in
that progressive metabolite changes were observed even among neuroasymptomatic
individuals with virologic suppression. Together these findings suggest that that HIV-
associated bran injury can progress in the absence of overt symptoms, and that effective
antiretroviral treatment may not be sufficient to prevent this complication.
There have been few MRS prospective studies reported (Kantarci et al, 2007; Olson et al,
2008; Pilatus et al, 2009; Schott et al, 2010). Metabolite levels in healthy controls acquired
using similar methods as described here remain relatively unchanged over time compared to
those observed in the study patient. In this study, longitudinal phantom measurements were
acquired with each imaging session to assess whether changes observed in the HIV subjects
could be attributed to scanner drift or measurement instability. The findings were consistent
with those reported in previous studies among healthy adults and argue strongly that the
observed changes were due to biological rather than scanner-related factors.
The current findings expand on a large body of cross sectional evidence showing the
association between HIV infection and various patterns of brain injury as measured by MRS
(Chang et al, 2004; Lopez-Villegas et al, 1997; Meyerhoff et al, 1999; Mohamed et al, 2010;
Paul et al, 2007; Tracey et al, 1996; Urenjak et al, 1993; Yiannoutsos et al, 2004). Observed
abnormalities have consistently included elevated levels of the inflammatory markers Cho
and MI among HIV-infected individuals regardless of cognitive status whereas decrease in
NAA, a marker of neuronal integrity, has consistently been observed in individuals with
NCI, suggesting that neural dysfunction may be necessary in its expression (Chang et al,
2004; Harezlak et al, 2011; Mohamed et al, 2010; Paul et al, 2007; Yiannoutsos et al, 2004).
It is of interest then that, in the setting of chronic infection and treatment, progressive
decreases in NAA both in grey and white matter were observed in NA subjects suggesting
these individuals may be at risk for developing NCI. In contrast symptomatic subjects
(ADC>1) although showing similar patterns of change, had more extensive involvement of
the basal ganglia, consistent with earlier observations that injury to this region is a critical
event leading to symptomatic impairment (Brew et al, 1995; Navia et al, 1986a; Rostasy et
al, 1999). Further, the prominent changes in the cortical grey matter across the groups are
consistent with recent reports of persistent cortical atrophy in HIV-infected people (Cohen et
al, 2010a; Cohen et al, 2010b; Thompson et al, 2005), and suggest that the pattern of HIV-
associated brain dysfunction in the context of treatment may have evolved from what was
previously considered a subcortical disorder (Heaton et al, 1995; Navia et al, 1986a; Navia
et al, 1986b).
Decreases in Glx comprised the largest metabolite change observed across the clinical
groups, particularly in the MFC and BG. The Glx peak represents the levels of both
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glutamine and glutamate and may change in response to events affecting glial and neuronal
function (Urenjak et al, 1993). Recent cross-sectional studies in HIV have found significant
deceases in Glx even in NA individuals (Harezlak et al, 2011; Mohamed et al, 2010).
Changes in Glx may thus represent a critical event that occurs prior to the onset of
neurocognitive symptoms, and may offer a sensitive biomarker of neural health in the early
stages of infection. Together with NAA, these metabolites may provide a useful approach to
monitoring cerebral function over the course of HIV disease in the era of CART.
The observed declines in Cho, a marker of membrane turnover, were unexpected as was the
relative absence of changes in MI, a measure of cellular osmotic changes and glial cell
proliferation (Lopez-Villegas et al, 1997; Meyerhoff et al, 1999; Tracey et al, 1996; Urenjak
et al, 1993). In contrast to the findings from cross sectional studies, this observation suggests
these two metabolites can in fact dissociate, possibly as a consequence of the different
cellular processes they reflect. Combined, these results suggest a pattern of continuing
neural injury in the setting of stable brain inflammation. The reason for this is not presently
known but it is possible that CART may be effective in stabilizing inflammatory responses
while other neuroactive events remain unchecked, resulting in membrane damage with loss
of choline containing compounds. Quantitative pathological studies are needed to confirm
this model. The decrease in creatine, generally considered a marker of energy metabolism,
was found only in MFC and BG, suggesting these regions may be particularly vulnerable to
global disturbances in metabolic function.
This is the first study to show associations between longitudinal changes in cerebral
metabolites and cognitive decline, and expands on a small number of cross-sectional
findings (Mohamed et al, 2010; Paul et al, 2007). Notably, global cognitive decline was
associated with decreases in Glx levels in the frontal white matter and the basal ganglia, and
marginally with decrease in NAA in the basal ganglia. The Glx finding is particularly
noteworthy, as the role of this metabolite in cognitive function has remained uncertain. The
current findings also extend a recent study showing significant associations of Glx levels
with executive function, working memory, and motor impairments, and together suggests
decreases in Glx may contribute importantly to HIV-associated neurocognitive impairment
(Mohamed et al, 2010).
The basis for the current findings is unclear but may be due to the effects of one or more
host or disease-related factors. Several studies pre-CART had identified plasma and CSF
HIV RNA levels in addition to low current CD4 as important risk factors for neurocognitive
impairment (Ellis et al, 1997; McArthur et al, 1997). More recently, several groups have
reported significant associations between nadir CD4, brain atrophy and neurocognitive
impairment (Cohen et al, 2010b; Heaton et al, 2011). However, preliminary findings suggest
that mechanisms contributing to progressive brain injury may involve complex relationships
among several factors, including HIV viral load, CD4 levels, duration of infection and of
treatment, and aging. We have recently shown that the chemokines, MCP-1 and IP10, are
associated with decreases in NAA suggesting that markers of immune activation and
inflammation contribute to neuropathogenesis (Letendre et al, 2011). In addition, underlying
comorbid disorders such as hepatitis C, diabetes mellitus, obesity, possibly mediated
through one or more inflammatory factors, may also affect risk (Valcour et al, 2004;
Valcour et al, 2005; van Gorp and Hinkin, 2005). Further studies are needed to disentangle
the effects of these factors and their relationships to varying patterns of brain injury.
Results from the current study indicate that progressive brain injury continues to occur in
medically stable HIV-infected persons on effective antiretroviral therapies, and these
changes are related to declines in cognitive function over time. These results further support
MRS as a sensitive measure of HIV-associated brain injury even in neurocognitively
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asymptomatic individuals, and points to its potential value, in combination with cognitive
assessments, in monitoring disease progression and response to treatment. These findings
suggest that careful monitoring of neurological function in HIV-infected persons is
warranted in the setting of chronic disease and treatment.
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Longitudinal changes in absolute concentrations of NAA, Cho, Cr, and Glx in the midfrontal
cortex (MFC). Each thin grey line represents the metabolite concentration level for each
participant at all observed time points, while the red solid line gives the estimate of the mean
metabolite population trajectory and broken lines give 95% pointwise confidence intervals
of the estimated mean.
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Table 1
Demographic and relevant clinical information.
ADC Stage Total
0 0.5 1+
N 138 48 40 226
Age (years) 46 (41, 52) 49 (44, 52) 49 (43, 58) 47 (41, 52)
Gender (% male) 112 (81%) 40 (83%) 36 (90%) 188 (83%)
Ethnicity (% Caucasian) 100 (72%) 27 (56%) 30 (75%) 157 (69%)
College education or higher 84 (61%) 27 (56%) 27 (68%) 138 (61%)
CD4 count (cells/ml) 327 (196, 495) 330 (249, 428) 307 (194, 466) 326 (196, 495)
Nadir CD4 (cells/ml) 40 (13, 94) 36 (15, 69) 38 (12, 116) 37 (13, 94)
Plasma viral load (% undetectable) 117 (85%) 37 (77%) 30 (75%) 184 (81%)
CSF viral load (% undetectable)* 26 (63%) 12 (75%) 22 (88%) 60/82 (73%)
HIV infection duration (years) 12 (5, 17) 8.5 (5.75, 16) 12 (9.5, 17.5) 11.5 (5, 17)
CART treatment duration (years) 1.53 (0.89, 2.90) 1.45 (0.57, 2.82) 1.58 (0.73, 3.52) 1.53 (0.89, 2.90)
*
CSF viral load data were available for 82 participants.
Note: Values reported as median (Q1, Q3) unless noted otherwise. CART = combination antiretroviral therapy. No significant group differences
were found in any of the variables (p > .05).
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Table 2
Neuropsychological tests administered as part of this study organized by cognitive domains. Details of the
individual tests have been described elsewhere (Heaton et al, 1995; Rippeth et al, 2004).
Cognitive Domains Tests
Processing Speed WAIS-III Digit Symbol
WAIS-III Symbol Search
Trail Making: Part A
Verbal Fluency Controlled Oral Word Association (FAS) - Correct Words
Animal Naming - Correct Words
Action Fluency - Correct Words
Executive Function Trail Making: Part B
Stroop Test
Working Memory Paced Auditory Serial Addition Task
WAIS-III Letter Number Sequencing
Learning Hopkins Verbal Learning Test - Immediate Recall
Benton Visual Memory Test - Immediate Recall
Memory Hopkins Verbal Learning Test - Delayed Recall
Benton Visual Memory Test - Delayed Recall
Psychomotor Grooved Pegboard
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